Navigation Links
Trianni Announces Launch of Its Optimized Human Antibody Transgenic Mouse
Date:9/26/2013

EMERYVILLE, Calif., Sept. 26, 2013 /PRNewswire/ -- Trianni, Inc., a Californian biotechnology company, announced today the launch of its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates.

Monoclonal antibodies are the most successful biologic therapeutics on the market.  More than thirty have been approved for use in humans and hundreds are currently undergoing testing in clinical trials for a broad range of clinical conditions.  Among the options currently available for therapeutic antibody discovery, transgenic mice, such as the Trianni Mouse, are unmatched in their suitability for meeting pharmaceutical research needs.

The Trianni Mouse is an advanced transgenic platform featuring highly engineered antibody genes, generated using state-of-the-art DNA synthesis and genome modification methodology.  It replicates the full antibody-producing capacity – or repertoire – of a human being, and features many enhancements designed to improve its performance as a discovery vehicle.  Trianni's technology represents a significant and highly distinctive advance over existing human antibody transgenic mouse platforms.

The Trianni Mouse platform is now available, with additional variations to follow in the first half of 2014.

Trianni is actively seeking partnerships with interested biotechnology and pharmaceutical companies.  For further information on the technology, please visit trianni.com.

About the Trianni Mouse Antibody Discovery Platform

Trianni took a radically different approach to generating its transgenic mouse platform.  This began with the design and chemical synthesis of novel chimeric antibody 'gene segments' each composed of human antibody-coding information combined directly with mouse regulatory information.  Well over a hundred distinct segments were assembled into large arrays, which were then embedded in the mouse genome in place of their normal mouse counterparts.  The outcome was antibody genes that are optimized for function in the mouse yet nonetheless express a full repertoire of human variable domains.  The Trianni mouse that carries these unique genes is a validated platform ideal for the isolation of therapeutic monoclonal antibodies.

About Trianni

Trianni was formed in 2010 with the sole focus of developing and distributing its optimized antibody discovery platform, The Trianni Mouse. It has been funded throughout from private sources. The company has administrative and research facilities in the San Francisco Bay Area and in Germany, respectively. Its executive team includes academic molecular immunologists and business development personnel with successful track records in biotechnology.

Contact:

Michael Greenberg, Chief Business Officer
Phone: +1 650-530-0640
Email: Michael.greenberg@trianni.com

 


'/>"/>
SOURCE Trianni
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)...   TyrNovo , s NT219 ... cancer drug resistance and would ...   NT219 is a novel proprietary ... oncogenic pathways ( IRS1/2 and STAT3) highly ... the tumor .   NT219 has ...
(Date:1/12/2017)... 2017 This new report from VPGMarketResearch contains ... of the German hospital microbiology testing market, including:  ... hospital laboratory practice, as well as key economic, regulatory, ... during the next ten years.  ... and etiology of major infectious diseases and microorganisms.  ...
(Date:1/12/2017)... -- Harrington Discovery Institute at University Hospitals in ... Drug Discovery Foundation (ADDF) have expanded their collaboration ... Alzheimer,s disease. Together, the two organizations will jointly ... academic researchers. By leveraging their combined expertise, investment, ... will advance Alzheimer,s disease drug discovery projects of ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... The JPR Group, a ... announce that it will be assisting HackensackUMC Mountainside with its public relations efforts, ... servicing all surrounding towns. The firm will be working closely with HackensackUMC Mountainside’s ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... frame transition from one clip to the next. , To use “Cut-Out First” ...
(Date:1/13/2017)... NJ (PRWEB) , ... January 13, 2017 , ... ... sale companions, will be showcasing the next generation companion scanner and data collector at ... The new KDC270 has been created as an answer to the market’s need for ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about ... they brush their teeth. Sadly, most dental hygiene products in the market contain chemical ... For these people, continuing their daily oral care routine to keep their teeth white ...
(Date:1/13/2017)... ... 2017 , ... MyGenetx, a molecular laboratory headquartered in middle Tennessee is proud ... Smith, RD, LD, will serve on the 2017 TBCC Board. , Kris ... and one year as Vice President. She will oversee the newly elected board of ...
Breaking Medicine News(10 mins):